Combined HSV-1 Recombinant and Amplicon Piggyback Vectors: Replication-Competent and Defective Forms, and Therapeutic Efficacy for Experimental Gliomas

Journal of Gene Medicine

Volumn 1, Issue 3, 1999, Pages 176-185

  Pechan, Peter A ^a,b   Herrlinger, Ulrich ^a,c   Aghi, Manish ^a   Jacobs, Andreas ^a,d   Breakefield, Xandra O ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Amplicons; Brain tumors; Cancer; Gene therapy; Herpes simplex virus; Virus vectors

Indexed keywords

HERPES; HUMAN HERPESVIRUS 1; MUS MUSCULUS;

ANIMAL; ARTICLE; CELL LINE; CERCOPITHECUS; DEFECTIVE VIRUS; GENE THERAPY; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; GLIOSARCOMA; HAMSTER; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; IMMEDIATE EARLY GENE; LACTOSE OPERON; MALE; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHYSIOLOGY; PLASMID; RAT; VERO CELL; VIRUS REPLICATION;

ANIMALS; BASE SEQUENCE; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DEFECTIVE VIRUSES; GENE THERAPY; GENES, IMMEDIATE-EARLY; GENETIC VECTORS; GLIOSARCOMA; HELPER VIRUSES; HERPESVIRUS 1, HUMAN; LAC OPERON; MALE; MICE; MICE, NUDE; PLASMIDS; RATS; RECOMBINATION, GENETIC; VERO CELLS; VIRUS REPLICATION;

EID: 0033122033     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1521-2254(199905/06)1:3<176::aid-jgm35>3.0.co;2-t     Document Type: Article

References (38)

1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
2. Breakefield XO, DeLuca NA. Herpes simplex virus for gene delivery to neurons. New Biol 1991; 3: 203-218.
3. Breakefield XO, Kramm CM, Chiocca EA, Pechan PA. Herpes simplex virus vectors for tumor therapy. In The Internet Book of Gene Therapy. Cancer Therapeutics. In: Sobol RE, Scanlon KJ (eds). Stamford, Connecticut: Appleton & Lange, 1995; 41-56.
4. Kaplitt MG, Tjuvajev JG, Leib DA et al. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J Neurooncol 1994; 19: 137-147.
5. Boviatsis EJ, Park S, Sena-Esteves M et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
6. Mullaney J, Moss HW, McGeoch DJ. Gene UL2 of herpes simplex virus type 1 encodes a uracyl-DNA glycosylase. J Gen Virol 1989; 70: 449-454.
7. Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum Gene Ther 1997; 8: 533-544.
8. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
9. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
10. Andreansky SS, He B, Gillespie GY et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci. U S A 1996; 93: 11313-11318.
11. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448.
12. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-943.
13. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8: 2057-2068.
14. Frenkel N. Defective interfering herpesviruses. In The Human Herpesviruses. An Interdisciplinary Prospective, In: Nahmias AJ, Dowdle WR, Schinazy RS (eds). North-Holland: Elsevier, 1981; 91-120.
15. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
16. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
17. Pechan P, Chiocca EA, Chase M, Thompson RL, Corey DP, Breakefield XO. A novel herpes simplex virus 'piggyback' packaging system for amplicon vectors. Soc Neurosci Abst 1994; 20, 731.3.
18. Pechan PA, Fotaki M, Thompson RL et al. A novel packaging system piggyback for herpes simplex virus amplicon vectors. Hum Gene Ther 1996; 7: 2003-2013.
19. Berthomme H, Fournel S, Epstein AL. Increased transcomplementation properties of plasmids carrying HSV-1 origin of replication and packaging signals. Virol 1996; 216: 437-443.
20. Zhang X, O'Shea H, Entwisle C, Boursnell M, Efstathiou S, Inglis S. An efficient selection system for packaging herpes simplex virus amplicons. J Gen Virol 1998; 79: 125-131.
21. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I.Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974; 14: 8-19.
22. Preston VG, Davison AJ, Marsden HS, Timbury MC, Subak-Sharpe JH, Wilkie NM. Recombinants between herpes simplex virus types 1 and 2; analysis of genome structures and expression of immediate early polypeptides. J Virol 1978; 28: 499-517.
23. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
24. Rice SA, Knipe DM. Genetic evidence for two distinct transactivation functions of the herpes simplex virus - protein ICP27. J Virol 1990; 64: 1704-1715.
25. Samaniego LA, Webb AL, DeLuca NA. Functional interactions between herpes simplex virus immediate-early proteins during infection: gene expression as a consequence of ICP27 and different domains of ICP4. J Virol 1995; 69: 5705-5715.
26. Rice SA, Su L, Knipe DM. Herpes simplex virus type 1 a protein ICP27 possesses separable positive and negative regulatory activities. J Virol 1989; 63: 3399-3407.
27. Sanger F, Nicklen S, Coulson A. . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74: 5463-5467.
28. Johnson PA, Friedmann T. Replication-defective recombinant herpes simplex virus vectors. Methods Cell Biol 1994; 43: 211-230.
29. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci US A 1987; 84: 156-160.
30. Feinberg A, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 6-13.
31. McCarthy AM, McMahan L, Schaffer PA. Herpes simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of transcription and are DNA deficient. J Virol 1989; 63: 18-27.
32. Wei MX, Tamiya T, Chase M et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
33. Spear M, Herrlinger U, Rainov N, Pechan P, Weissleder R, Breakefield XO. Targeting gene therapy vectors to CNS malignancies. J Neurovirol 1998; 4: 133-147.
34. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis; isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
35. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant gliomas. Cancer Gene Ther 1997; 4: 222-228.
36. Jacobs A, Jacoby DR, Herrlinger U, et al. Treatment of brain tumors using helper virus-free HSV-1 amplicon and HSV/AAV hybrid amplicon vectors. Submitted.
37. Miyatake S, Iyer A, Martuza RL, Rabkin SD. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997; 71: 5124-5132.
38. Alemany R, Lai S, Lou YC, Jan H-Y, Fang X, Zhang W-W. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 1999; 6: 21-25.